Regenlab USA Inc.

expected

Not yet set

status

Filed with SEC

proposed ticker

RGNA

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Underwriters (from filing)

StoneX Financial Inc

Overview

— AI-generated from the filing, see note below

Business overview

RegenLab is a science-driven regenerative medicine company focused on developing a range of medical products utilizing proprietary blood-processing devices and other technologies. The company operates from three manufacturing sites in New Jersey (USA), Paris (France), and Monthey (Switzerland), and holds over 70 patents. It currently offers numerous products across various regulatory stages for treatments in joint preservation, soft tissue healing, and related areas. Its products are marketed globally, with direct sales and distribution partnerships across key markets.

Revenue model

RegenLab generates revenue primarily through the sale of medical products, specifically within regenerative medicine technology, including PRP systems, wound care products, and other therapies. Revenue streams are supported by clinical evidence demonstrating effectiveness across various therapeutic domains.

Competitive strengths

Extensive patent portfolio with over 70 granted patents
Integrated control over R&D, manufacturing, and regulatory processes
Established presence in key global markets
Strong clinical evidence supporting product effectiveness and value proposition

Risk factors

High degree of risk associated with investing in medical technology companies
Potential regulatory hurdles in product approval processes
Market competition from other regenerative medicine and medical device companies
Dependence on sales in North America and Europe for revenue generation

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The proposed ticker is RGNA. Underwriters on the deal include StoneX Financial Inc. Regenlab USA Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Regenlab USA Inc..

Biotech IPOs United States IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/regenlab-usa" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Regenlab USA Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/regenlab-usa?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/regenlab-usa/opengraph-image

Attribution text

Regenlab USA Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/regenlab-usa?utm_source=embed&utm_medium=text&utm_campaign=regenlab-usa

Track this IPO

Get emailed when Regenlab USA Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

What is Regenlab USA Inc.'s ticker symbol?

Regenlab USA Inc.'s proposed ticker is RGNA.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 27, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.